Eli Lilly will acquire Merida Biosciences for up to $2.875 billion, gaining MER511, a Phase I therapy targeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results